MedPage Today2d
Gene Therapy May Be a Game Changer for Transfusion-Dependent Thalassemia
The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent ...
Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move
Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will ...
Thalassemia Market Research by Treatment Type, Type, Distribution Channel, and Region - Global Forecasts 2034-2034
Global Thalassemia Market Global Thalassemia Market Dublin, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The "Thalassemia Market by ...
UK health system to offer cutting-edge gene therapy for sickle cell disease
The therapy involves taking stem cells out of a patient's bone marrow and editing a gene in the cells in a laboratory and ...
Yahoo Finance20d
YolTech Therapeutics to Initiate a Clinical Trial for YOLT-204, a First-in-Class Bone Marrow-Targeted In Vivo Gene Editing Therapy for β-Thalassemia
SHANGHAI, Jan. 20, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage gene editing company dedicated to delivering lifelong cures, announced the initiation of a clinical trial for YOLT ...
Medindia20d
YolTech Therapeutics to Initiate a Clinical Trial for YOLT-204, a First-in-Class Bone Marrow-Targeted In Vivo Gene Editing Therapy for ß-Thalassemia
YolTech Therapeutics, a clinical-stage gene editing company dedicated to delivering lifelong cures, announced the initiation of a clinical trial for YOLT-204 , an investigational ...
Investing28d
Editas Medicine advances gene editing treatments
Despite these changes, Editas Medicine reported preclinical success in hematopoietic stem cells gene editing, a potential treatment for sickle cell disease and beta thalassemia. Several analyst ...